Design, synthesis, and evaluation of tetrahydroquinoline and pyrrolidine sulfonamide carbamates as γ-secretase inhibitors

Abstract γ-Secretase is a key enzyme involved in the production of β-amyloid peptides which are believed to play a critical role in the onset and progression of Alzheimer’s disease (AD). As such, inhibition of γ-secretase has been an attractive approach to AD therapy. In this paper, the design, synthesis, and evaluation of tetrahydroquinoline and pyrrolidine sulfonamide carbamates as γ -secretase inhibitors are described.

[1]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[2]  D. Selkoe,et al.  Alzheimer disease: mechanistic understanding predicts novel therapies. , 2004 .

[3]  W. Greenlee,et al.  Discovery of γ-secretase inhibitors efficacious in a transgenic animal model of Alzheimer’s disease , 2007 .

[4]  T. L. Gilchrist,et al.  Benzocarbacephems from quinolines , 1998 .

[5]  E. Parker,et al.  Biochemical characterization of the gamma-secretase activity that produces beta-amyloid peptides. , 2001, Biochemistry.

[6]  I. Churcher,et al.  γ-Secretase as a Therapeutic Target for the Treatment of Alzheimers Disease , 2005 .

[7]  Zhiqiang Zhao,et al.  Tetrahydroquinoline sulfonamides as γ-secretase inhibitors , 2007 .

[8]  D. Selkoe,et al.  Defining molecular targets to prevent Alzheimer disease. , 2005, Archives of neurology.

[9]  W. Greenlee,et al.  2,6-Disubstituted N-arylsulfonyl piperidines as γ-secretase inhibitors , 2007 .

[10]  J. Treanor,et al.  Fenchylamine sulfonamide inhibitors of amyloid beta peptide production by the gamma-secretase proteolytic pathway: potential small-molecule therapeutic agents for the treatment of Alzheimer's disease. , 2000, Journal of medicinal chemistry.

[11]  A Klug,et al.  Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Clifford J. Woolf,et al.  Pain: Moving from Symptom Control toward Mechanism-Specific Pharmacologic Management , 2004, Annals of Internal Medicine.